November 30, 2025

To, **BSE Limited**, 25, P. J. Towers, Dalal Street, Mumbai – 400 001 **Ref:** Company Scrip Code: 532834	To, The Manager, Listing Department, **National Stock Exchange of India Ltd.**, Exchange Plaza, Bandra Kurla Complex, Bandra (East), Mumbai- 400051 **Ref:** Symbol: CAMLINFINE || Series: EQ

Sub: **Outcome of the meeting of the Securities Issue and Allotment Committee of the Board of Directors of Camlin Fine Sciences Limited (the "Company") held on November 30, 2025 - Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")**

Dear Sir/Madam,

This is with reference to our intimations dated February 24, 2025, June 25, 2025, September 24, 2025, September 25, 2025, September 29, 2025, October 17, 2025 and October 29, 2025 in relation to the issue of up to 41,06,181 fully paid up equity shares of the Company at a price of ₹ 247.69 per equity share (which includes a premium of ₹ 246.69 per equity share), to the proposed allottees/investors ("**Allottees**"), aggregating up to ₹ 101,70,59,971.89 (Rupees One Hundred One Crore Seventy Lakh Fifty-Nine Thousand Nine Hundred Seventy-One Rupees and Eighty-Nine Paise only), for a consideration other than cash, being consideration towards the acquisition of ordinary shares of Vinpai, a French société anonyme ("**Vinpai**"), in accordance with the terms of the share purchase agreement dated February 24, 2025 and amendments thereof ("**SPA**") amongst the Company and Vinpai, by way of a preferential issue on a private placement basis ("**Preferential Issue**").

In relation to the aforesaid Preferential Issue and pursuant to members' resolution dated October 29, 2025, and in-principal approval received from the National Stock Exchange of India Limited and the BSE Limited on November 18, 2025, and pursuant to credit of 27,23,316 ordinary shares of Vinpai by the Allotees into the Company's demat account held with Financière d'Uzès, Paris, the Securities Issue and Allotment Committee of the Company (the "**Committee**") at its meeting held today i.e. on Sunday, November 30, 2025 , considered and approved the allotment of 41,06,181 fully paid up equity shares of the Company at a price of ₹ 247.69/- per equity share (which includes a premium of ₹ 246.69/- per equity share), aggregating to a consideration of ₹ 101,70,59,971.89/- (One Hundred One Crore Seventy Lakh Fifty-Nine Thousand Nine Hundred Seventy-One Rupees and Eighty-Nine Paise only), for consideration other than cash, to the Allottees pursuant to the Preferential Issue (as detailed in the Annexure 1).

Accordingly, the paid-up equity share capital of the Company has increased from ₹ 18,79,80,432 to ₹ 19,20,86,613 by addition of 41,06,181 equity shares of the Company.

The said fully paid-up equity shares allotted shall rank pari-passu in all respect with the existing fully paid-up equity shares of the Company.

Pursuant to the aforesaid allotment, the transaction contemplated in terms of the SPA has been undertaken and completed. Accordingly, an update on the disclosure made on February 24, 2025 under

Regulation 30 read with Para A Part A of Schedule III of SEBI LODR Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 is enclosed as Annexure 2.

The meeting of the Committee commenced at 05:00 p.m. and concluded at 05:30 p.m.

We request you to take the aforesaid on record.

Thanking you,
Yours faithfully,
For Camlin Fine Sciences Limited

RAHUL SAWALE

Digitally signed by RAHUL SAWALE
Date: 2025.11.30 17:46:34 +05'30'

Rahul Sawale
Company Secretary & V. P. Legal

Encl.: a/a.

Registered Office:
Camlin Fine Sciences Limited, Floor 2 to 5, In G.S. Point, CST Road, Kalina, Santacruz (East), Mumbai 400 098.
CIN: L74100MH1993PLC075361

+91 22 6700 1000 +91 22 2832 4404 corporate@camlinfs.com www.camlinfs.com

Camlin Fine Sciences

Annexure 1

Sr. No.	Name of allottees	Category (Promoter / Public)	Pre-issue Shareholding Structure		No. of Equity Shares allotted	Number of Shares held in Vinpai	Consideration (in ₹) determined for Swap Shares/ issue price	Post-issue Shareholding Structure*	
			Number	% of shares				Number	% of shares
1.	Cyrille Damany	Public	NIL		12,50,161	8,29,136	30,96,52,378.09	12,50,161	0.64
2.	Philippe Le Ray	Public			7,76,510	5,15,000	19,23,33,761.90	7,76,510	0.40
3.	Alexandre Moranville	Public			3,47,263	2,30,313	8,60,13,572.47	3,47,263	0.18
4.	Chris Project	Public			12,71,855	8,43,524	31,50,25,764.95	12,71,855	0.65
5.	Saffelberg Investments	Public			4,60,392	3,05,343	11,40,34,494.48	4,60,392	0.23
Total					**41,06,181**	**27,23,316**	**101,70,59,971.89**	**41,06,181**	**2.10**

** Post-preferential issue shareholding is on a fully diluted basis.*

RAHUL SAWALE
Digitally signed by RAHUL SAWALE
Date: 2025.11.30 17:47:46 +05'30'

Annexure 2

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	**<u>Name of the target entity:</u>** Vinpai, a French société anonyme ("**Vinpai**") **<u>Details of target entity:</u>** Vinpai was incorporated & founded in 2011 by Cyrille Damany and Philippe Le Ray. Vinpai is an ingredien'tech company specializing in the design, manufacture and marketing of algae, plants, mineral and fiber-based functional ingredients offering manufacturers natural alternatives to chemical additives. Positioned in the most promising market segments, Vinpai now supports manufacturers in the food industry, its historical market, cosmetics and nutraceuticals, thanks to cross-technology know-how, enabling them to increase the nutritional qualities of their finished products. The combination and association of ingredients and food additives allows manufacturers to accelerate their development, optimize their production costs and generate profitability. Operating from two sites, in Saint-Dolay (Morbihan) and near the port of Saint-Nazaire, Vinpai has developed more than 3,500 formulas and now has 43 employees. Vinpai is listed on the Euronext Growth Paris since its successful IPO on July 19, 2023. During its financial year 2023 (i.e. from Jan. 2023 to Dec. 2023), Vinpai generated a turnover of € 7.9 million with a loss of € 3.4 million (After Tax). During its financial year 2024, Vinpai generated a turnover of € 9.157 million.
2.	Whether the acquisition would fall within related party transaction(s) and-whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	No
3.	Industry to which the entity being acquired belongs	Food, Cosmetics and Medical industry
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its	Pursuant to SPA dated February 24, 2025, the Company has acquired 27,23,316 ordinary shares constituting a majority stake in Vinpai representing 78.68% of Vinpai's outstanding share capital.

	business is outside the main line of business of the listed entity)	The consideration payable to the Sellers for the acquisition of Vinpai shares by the Company was discharged by allotment 41,06,181 equity shares of the Company to the Sellers (‘**Share Swap**’) at a price of ₹ 247.69/- per Equity Share (which includes a premium of ₹ 246.69/- per Equity Share), aggregating to a consideration of ₹ 101,70,59,971.89/-. The price of each of the Company’s shares for the said Share Swap was calculated in compliance with pricing rules for preferential issue set out under Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 (‘**SEBI ICDR Regulations**’). Vinpai is an ingredien'tech specializing in the design, manufacture and marketing of functional ingredients based on algae, plants, minerals, and fibers, offering manufacturers natural alternatives to chemical additives. Positioned in the most promising market segments, Vinpai provides support to food, cosmetics and nutraceutical manufacturers, thanks to its cross-technology know-how, enabling them to upgrade the nutritional qualities of their end products. The combination of mixing of ingredients and food additives enables manufacturers to accelerate their development, optimize their production costs and generate profitability. Vinpai has a subsidiary namely Based Algae and Plants, which is mainly a sales arm and a vehicle company. Vinpai has presence with Europe, North Africa, West Africa, and South-east Asia being key end-markets for the company. The Company is confident of increasing the foot print of Vinpai’s product into feed market by extending the technology in production and marketing. This would give additional revenue which are not available hitherto Vinpai. From the perspective of the Company, the technological prowess of Vinpai provides an interesting avenue for increasing the basket of its existing product range, usage of technology to improve the quality and yields of the existing products. This acquisition would pave way to enter into new technological advancements and thus help to increase the customer satisfaction and growth of business.
5.	Brief details of any governmental or regulatory approvals required for the acquisition	The Company has received in-principal approval from the National Stock Exchange of India Limited and the BSE Limited on November 18, 2025 for the issuance of Company’s shares to the Sellers on preferential basis.

6.	Indicative time period for completion of the acquisition	The transaction contemplated in terms of the SPA has been undertaken and completed on November 30, 2025.
7.	Consideration - whether cash consideration or share swap or any other form and details of the same	Share Swap as stated in point 4 above.
8.	Cost of acquisition and/or the price at which the shares are acquired	Share Swap as stated in point 4 above: Price of the Company's per share which is calculated in compliance with and be not less than the pricing rules for preferential issue set out under Chapter V of the SEBI ICDR Regulations.
9.	Percentage of shareholding / control acquired and / or number of shares acquired	27,23,316 ordinary shares constituting 78.68% of Vinpai's outstanding share capital by our Company.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	Vinpai was incorporated & founded in 2011 by Cyrille Damany and Philippe Le Ray. Vinpai is an ingredient'tech company specializing in designing, manufacturing and selling algae, plant and mineral based functional ingredients. The aim of the company is to provide its customers / partners with the opportunity to substitute chemical additives with natural formulations in order to improve the nutritional qualities of their end products. Vinpai is listed on the Euronext Growth Paris since its successful IPO on July 19, 2023. The turnover of Vinpai for last 3 years is given below: **Year** — **Turnover (Euro in Million)** Jan. 2024 – Dec. 2024 — 9.2 Jan. 2023 – Dec. 2023 — 7.9 Jan. 2022 – Dec. 2022 — 6.2 Country of Operation – France

RAHUL SAWALE

Digitally signed by RAHUL SAWALE
Date: 2025.11.30 17:48:37 +05'30'